The Depo-Provera lawsuit 2026 litigation is entering its most critical phase yet. With general-causation Daubert hearings scheduled for June 24–26, 2026 in the Northern District of Florida, the outcome of a three-day courtroom battle will determine whether more than 5,500 consolidated claims move toward trial — or face collapse. Judge M. Casey Rodgers has set December 7, 2026 as the date for the first bellwether trial, and an unresolved preemption ruling from Pfizer looms as a parallel threat to thousands of claimants. For anyone tracking MDL 3140, the next two weeks are the most consequential in the history of this litigation.
The Depo-Provera MDL: Where Things Stand in June 2026
MDL 3140 was consolidated in the Northern District of Florida under Judge M. Casey Rodgers and has grown into one of the fastest-moving mass tort proceedings in the country. As of June 2026, over 5,508 claims have been consolidated into the MDL, with different reporting methodologies accounting for a range between 3,700 and 5,500-plus depending on whether filed cases or all consolidated claims are counted. Between February and May 2026 alone, more than 1,600 new lawsuits were filed — a pace that places the Depo-Provera lawsuit 2026 among the most rapidly expanding mass torts currently active in U.S. federal courts.
Monthly case management conferences have been held throughout 2026 at the U.S. District Courthouse in Pensacola, Florida, per the court’s pretrial order. Five pilot bellwether cases have been selected to represent the broader plaintiff pool, including Blonski v. Pfizer — in which a patient who began using the drug in 2002 was later found to have developed two meningiomas — and Wilson v. Pfizer, where a woman who used Depo-Provera from 1998 to 2019 suffered a stroke that revealed a Grade 1 meningioma. These cases were chosen to reflect a cross-section of injury types, duration of use, and medical outcomes that will shape how juries evaluate future claims.
Women who suffered brain injuries linked to Depo-Provera use may want to use a brain injury calculator to get a preliminary sense of what their claim may be worth before consulting legal counsel.
What the June 24–26 Daubert Hearings Actually Decide
The Daubert hearings scheduled for June 24–26, 2026 are not a trial on the merits — they are a gatekeeping proceeding in which Judge Rodgers will evaluate whether the plaintiffs’ general-causation experts meet the legal standard for admissible scientific testimony under Federal Rule of Evidence 702. If the court finds that plaintiffs’ experts reliably connect Depo-Provera use to meningioma development, the litigation moves forward on schedule toward the December 7 bellwether trial. If the experts are excluded or substantially limited, entire injury categories could be stripped from the case, and the MDL could face a significant setback.
The science underlying the general-causation arguments is substantial. A landmark 2024 French study published in the BMJ found that women using Depo-Provera had a 5.6-fold higher risk of developing intracranial meningioma compared to non-users. Plaintiffs’ experts are expected to rely heavily on that study, as well as on decades of accumulating research linking progestins to meningioma growth — including a 1983 study published in the European Journal of Cancer that identified progesterone receptors in meningioma cells, research that plaintiffs argue Pfizer had access to and failed to act upon.
Pfizer’s legal team is expected to challenge the methodology behind plaintiffs’ experts, arguing that observational epidemiological data cannot establish the causation standard required for admissibility. The outcome of these three days of hearings will reverberate across all 5,500-plus pending claims and set the evidentiary architecture for the first bellwether trial in December 2026.
Pfizer’s Preemption Defense: The Other Shoe Waiting to Drop
Separate from the Daubert proceedings, Pfizer has advanced a federal preemption defense that could be equally consequential for the Depo-Provera lawsuit 2026 litigation. The argument centers on the claim that the FDA’s prior denial of a meningioma-specific warning label request preempts state-law failure-to-warn claims — particularly for prescriptions written before July 2024. Under this theory, drug manufacturers cannot be held liable under state tort law for failing to add a warning that federal regulators had already declined to require.
The preemption issue remains unresolved as of June 2026, with a ruling described by legal observers as potentially dispositive for a large subset of claims. If the court sides with Pfizer on preemption, thousands of claimants whose prescriptions predate the regulatory inflection point could see their cases dismissed or severely weakened. The December 2025 FDA labeling update — which expressly referenced intracranial meningioma risk and recommended discontinuation upon diagnosis — gave post-July 2024 claimants a stronger footing, but pre-2024 prescriptions remain legally vulnerable under the preemption framework Pfizer is advancing.
Claimants whose injuries may fall into defective drug or device categories should consider using a medical malpractice calculator to understand how damages are typically structured in pharmaceutical failure-to-warn litigation.
Key MDL 3140 Statistics at a Glance
| Data Point | Figure | Source / Date |
|---|---|---|
| Total consolidated claims (June 2026) | 5,508+ | Sokolove Law, June 2026 |
| New lawsuits filed (Feb–May 2026) | 1,600+ | LegalExaminer, May 8, 2026 |
| Increased meningioma risk (Depo-Provera users) | 5.6× higher | BMJ French Study, 2024 |
| U.S. women who have used Depo-Provera | ~24.5% of sexually active women | Dolman Law / CDC data |
| Estimated settlement range | $150,000 – $800,000 | Lawsuit Information Center, 2026 |
| First bellwether trial date | December 7, 2026 | Judge Rodgers order, Jan 9, 2026 |
| Daubert hearing dates | June 24–26, 2026 | MDL 3140 Scheduling Order |
| FDA labeling update (meningioma warning) | December 2025 | FDA, December 2025 |
Who Is Filing and What Are the Stakes?
Approximately 24.5% of sexually active U.S. women have used Depo-Provera at some point, with higher usage rates documented among Hispanic and Black women — demographics that also face documented disparities in meningioma diagnosis and treatment access. The population of potential claimants is therefore extraordinarily broad, and the social equity dimensions of this Depo-Provera lawsuit 2026 litigation are not lost on plaintiffs’ attorneys or advocacy groups monitoring the MDL. More information on how federal courts handle consolidated mass tort proceedings is available through the United States Courts’ official explanation of court structure and role.
Estimated settlement values for resolved claims are expected to range from $150,000 to $800,000, with the higher end reserved for claimants who required surgical intervention, experienced significant neurological impairment, or used the drug for extended periods. These figures are preliminary and will be substantially shaped by how the Daubert hearings resolve and whether bellwether verdicts establish a damages baseline that both sides find instructive for settlement negotiations.
Parallel state court proceedings are also advancing in New York and Delaware, giving plaintiffs whose claims might be affected by federal preemption arguments an alternative litigation track. The interplay between the MDL and state proceedings will be an important strategic consideration for plaintiffs’ counsel in the months following the June hearings.
What Plaintiffs and Claimants Should Know Right Now
The Depo-Provera lawsuit 2026 litigation is at an inflection point that will not wait. The June 24–26 Daubert hearings represent a hard deadline after which the evidentiary landscape of the entire MDL will be reshaped. Claimants who have not yet filed — particularly those who used Depo-Provera for extended periods and subsequently developed meningioma — should be aware that statute of limitations periods vary by state and that individual claims must be properly filed to be included in any eventual global settlement. The CDC’s overview of brain tumor statistics and meningioma classification provides useful background on the medical conditions at the center of these claims.
The core allegation — that Pfizer knew as far back as 1983 of a potential link between medroxyprogesterone acetate and meningioma tumors and failed to update its warning label for decades — frames this as a classic failure-to-warn mass tort. The FDA’s December 2025 labeling update, which explicitly named intracranial meningioma as a risk and recommended discontinuation upon diagnosis, is seen by plaintiffs as a retroactive vindication of their core theory and a significant liability marker for Pfizer going forward.
For claimants exploring the full range of their potential damages across injury types, a personal injury settlement calculator can provide a general framework for understanding how settlement values are typically estimated in pharmaceutical mass tort litigation.
Frequently Asked Questions: Depo-Provera Lawsuit 2026
What are the June 2026 Daubert hearings and why do they matter?
The Daubert hearings scheduled for June 24–26, 2026 in MDL 3140 are a judicial gatekeeping proceeding where Judge M. Casey Rodgers will evaluate whether plaintiffs’ general-causation experts meet the legal standard for admissible scientific testimony. If the experts survive scrutiny, the litigation proceeds toward the December 7, 2026 bellwether trial. If excluded, major injury categories within the MDL could be dismissed or significantly weakened, making this the single most consequential procedural moment in the Depo-Provera lawsuit 2026 to date.
How many lawsuits have been filed in the Depo-Provera MDL as of June 2026?
As of June 2026, over 5,508 claims have been consolidated into MDL 3140 in the Northern District of Florida, according to Sokolove Law’s June 2026 data. Different counting methodologies used by various trackers place the number between 3,700 and 5,500-plus depending on whether only formally filed federal cases or all consolidated claims are counted. Between February and May 2026 alone, more than 1,600 new lawsuits were filed, making the Depo-Provera lawsuit 2026 one of the fastest-growing mass torts currently active in the U.S.
What is Pfizer’s preemption defense and how could it affect my claim?
Pfizer argues that the FDA’s prior denial of a meningioma-specific warning label request preempts state-law failure-to-warn claims under federal law — particularly for prescriptions written before July 2024. If the court accepts this defense, thousands of claimants whose Depo-Provera prescriptions predate that regulatory threshold could see their cases dismissed or substantially limited. A ruling on preemption is expected within months and is described by legal observers as potentially dispositive for a large portion of the Depo-Provera lawsuit 2026 claims currently pending in the MDL.
What does the science say about Depo-Provera and meningioma risk?
A 2024 French study published in the BMJ found that women using Depo-Provera had a 5.6-fold higher risk of developing intracranial meningioma compared to non-users. Research dating back to a 1983 study in the European Journal of Cancer identified progesterone receptors in meningioma cells — a finding plaintiffs argue Pfizer had access to for decades without updating its warning label. The FDA formally acknowledged the risk in December 2025 by updating Depo-Provera’s labeling to expressly reference intracranial meningioma and recommend discontinuation upon diagnosis.
What compensation amounts are being estimated for Depo-Provera lawsuit 2026 settlements?
Estimated settlement tiers for resolved Depo-Provera claims currently range from approximately $150,000 to $800,000, depending on injury severity, whether surgical intervention was required, neurological impairment sustained, and duration of Depo-Provera use. These are preliminary figures and will be significantly influenced by the outcome of the June 2026 Daubert hearings, the preemption ruling, and any verdicts returned in the December 7, 2026 bellwether trial. Individual claim values may differ substantially based on case-specific facts.
This article is provided for informational purposes only and does not constitute legal advice; readers should consult a licensed attorney regarding their specific legal situation.
Related reading: personal injury settlement calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.